Indo US Bio-Tech Q3 FY26 results: PAT drops 41% YoY, qualified opinion
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.5 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Revenue for Q3 FY26 was Rs 22.80 crore, down about 3% YoY, while net profit fell 41% to Rs 3.00 crore. Nine-month revenue grew 20% to Rs 84.41 crore but profit declined 11% to Rs 11.15 crore. EBITDA margin compressed to 15.6% from 19.6% a year ago. The auditor issued a qualified opinion, noting the company has not yet assessed the financial impact of the new Labour Codes effective November 2025.
Profitability under pressure despite revenue growth; auditor qualification on Labour Code impact adds uncertainty on employee costs.